← All trials
NCT05440240
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 30, 2022
- Primary completion
- Sep 30, 2024
- Completion date
- Dec 31, 2029
- First posted
- Jun 30, 2022
- Last posted
- Jul 6, 2022
- Enrollment
- 400
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Hospitalsenhed MidtLead sponsor
- Horsens HospitalStudy director
- Hospitalsenhed MidtReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.